CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY
Low toxicity, oncospecificity, immunogenicity and relatively frequent expression of CT antigens in many types of cancer justify their use in cancer immunotherapy. This review presents the data on CTA use in new clinical approaches to the malignant process control, developed from the ideas of the ant...
Main Authors: | D. I. Vodolazhsky, O. I. Kit, Kh. A. Mogushkova, A. A. Pushkin, N. N. Timoshkina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Tomsk National Research Medical Center of the Russian Academy of Sciences
2017-06-01
|
Series: | Sibirskij Onkologičeskij Žurnal |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/523 |
Similar Items
-
Cancer testis antigen and immunotherapy
by: Krishnadas DK, et al.
Published: (2013-04-01) -
Cancer/testis antigens (CTAs) expression in resected lung cancer
by: Jin S, et al.
Published: (2018-08-01) -
EFFECT OF ANTHRACYCLINE ANTITUMOR ANTIBIOTICS UPON TRANSCRIPTION ACTIVITY OF CANCER-TESTIS ANTIGENS IN MODEL EXPERIMENTS WITH HeLa CELLS
by: D. S. Kutilin, et al.
Published: (2019-07-01) -
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
by: Ghaneya Al-Khadairi, et al.
Published: (2019-07-01) -
Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
by: Kaipeng Xie, et al.
Published: (2019-01-01)